AstraZeneca's Enhertu wins EU approval for advanced gastric cancer
Lisa Maree Williams         

The European Commission has approved AstraZeneca's (NASDAQ:AZN) Enhertu (trastuzumab deruxtecan) as a monotherapy forÂ HER2 positive gastric or gastroesophageal junction adenocarcinoma.
The approval is the first for a HER2 directed therapy for gastric cancer in the EU in more than 10 years.
On Friday, an advisory panel of the European Medicines Agency recommended that Enhertu be approved as a monotherapy for unresectable or metastatic HER2âlow breast cancer.